Medical Condition News

RSS

Study: Larger dose of ARBs is more effective in heart failure patients

A larger dose of angiotensin receptor blockers (ARBs) is more effective than a smaller dose in heart failure patients, researchers said at the American Heart Association's Scientific Sessions 2009.

18 Nov 2009

Gene that tells embryonic stem cells when to stop producing neurons identified

Researchers from North Carolina State University have identified a gene that tells embryonic stem cells in the brain when to stop producing nerve cells called neurons. The research is a significant advance in understanding the development of the nervous system, which is essential to addressing conditions such as Parkinson's disease, Alzheimer's disease and other neurological disorders.

18 Nov 2009

A fact-based media briefing on bipolar disorder in Nova Scotia

An estimated 26,000 Nova Scotians live with bipolar disorder. Often stigmatized in popular culture, the experience of bipolar disorder varies from one person to the next and almost always has a drastic impact on how individuals think, behave and function.

18 Nov 2009

Pluristem’s PLX-PAD holds promise for critical limb ischemia

Pluristem Therapeutics Inc. today announced that safety and potential efficacy parameters were demonstrated by the three month follow up data from the first patient ever to receive its placenta derived cell therapy product, PLX-PAD. The patient is participating in a Phase I dose-escalating clinical trial in Europe with PLX-PAD, the company’s leading product candidate for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD).

18 Nov 2009

The Center for Modeling Optimal Outcomes discovers causal path of autism

During its research into the application of neuroscience in business, a New Jersey based think tank, The Center for Modeling Optimal Outcomes®, LLC (The Center) made an inadvertent and amazing discovery.

18 Nov 2009

Cancer-fighting protein successfully placed directly into solid tumors and turned on

Experiments at the Pioneer Valley Life Sciences Institute (PVLSI) at Baystate Medical Center in Springfield, Mass., reported in a recent British Journal of Cancer, confirm that University of Massachusetts Amherst chemical engineer Neil Forbes' delivery and trigger system has for the first time successfully placed TRAIL, a cancer-fighting protein, directly into solid tumors and on cue, turned it on. The treatment improved the 30-day survival time of mice with mammary tumors from 0 to 100 percent.

18 Nov 2009

Findings of Merck's anacetrapib phase IIb study presented at the AHA sessions

In a phase IIb study in 589 patients with primary hypercholesterolemia or mixed hyperlipidemia treated with anacetrapib as monotherapy or co-administered with atorvastatin, there were persistent lipid effects in the higher dose arms in both the monotherapy and co-administration treatment groups eight weeks after stopping active therapy with anacetrapib.

18 Nov 2009

Cardiologists detect atherosclerosis in ancient Egyptian mummies

A cardiologist at Saint Luke's Mid America Heart Institute and his research colleagues from Cairo, Milwaukee, and Mission Viejo, Calif., have detected hardening of the arteries in 3,500-year-old Egyptian mummies, indicating that heart disease is not just a condition found in modern humans.

18 Nov 2009

Ambrisentan improves health and exercise capacity of PAH patients, find researchers

In one of the few studies of the long-term effects of medication in the treatment of pulmonary arterial hypertension (PAH) disease, a team of researchers found the health and exercise capacity of PAH patients improved after two years of treatment with ambrisentan, according to a study published in the current edition of the Journal of the American College of Cardiology.

18 Nov 2009

CRESTOR reduces major cardiovascular events in women by 46%

A new analysis of the JUPITER trial, released today at the American Heart Association meeting in Orlando, Florida, demonstrates that CRESTOR (rosuvastatin calcium) 20mg reduced first major cardiovascular events by 46%.

18 Nov 2009

Developmental biologists to participate in $100 million federal 'Bench to Bassinet' network

Developmental biologists at the University of Pittsburgh have been chosen to participate in a $100 million federal "Bench to Bassinet" network that is dedicated to learning about the formation of the cardiovascular system and applying that knowledge to create new diagnostic and intervention strategies for congenital heart disease.

18 Nov 2009

Data demonstrate that danger of low levels of HDL is not reduced by statin treatment

Data released today at the American Heart Association (AHA) Scientific Sessions 2009 define the increased risk of heart attacks and cardiovascular disease in patients with low levels of HDL-C (known as "good cholesterol"). The data also determine that statins are unable to significantly impact the heart attack or cardiovascular disease risks associated with low HDL-C.

18 Nov 2009

World's first intra-arterial cerebral infusion of Avastin directly into a patient's malignant brain tumor

Neurosurgeons from NewYork-Presbyterian Hospital/Weill Cornell Medical Center performed the world's first intra-arterial cerebral infusion of Avastin (bevacizumab) directly into a patient's malignant brain tumor. This novel intra-arterial (IA) technique may expose the cancer to higher doses of the drug therapy, while possibly sparing the patient common side effects of receiving the drug intravenously (IV) or throughout their body.

18 Nov 2009

Updated clinical data from Poniard Pharmaceuticals' picoplatin Phase 2 trial announced

Poniard Pharmaceuticals, Inc. today announced updated clinical data from its randomized, controlled Phase 2 trial of picoplatin in patients with metastatic colorectal cancer (CRC).

18 Nov 2009

NeoPharm presents LE-DT Phase I data at the AACR conference

NeoPharm, Inc. today announced the results of a Phase I clinical trial of Liposome Encapsulated Docetaxel (LE-DT) an active component of Taxotere® at a joint International Conference of the American Association for Cancer Research (AACR), the National Cancer Institute (NCI) and the European Organization for Research and Treatment of Cancer (EORTC) being held in Boston, MA.

18 Nov 2009

Transcendental Meditation may be effective in reducing BP and psychological distress

"The Transcendental Meditation Program, a widely-used standardized program to reduce stress, showed significant decreases in blood pressure and improved mental health in young adults at risk for hypertension," said David Haaga, PhD, co-author of the study and professor of psychology at American University in Washington, D.C.

18 Nov 2009

New research may play a vital role in assisting patients with chronic lung disease

Dr Lori Calvert's research involved testing patients with Chronic Obstructive Pulmonary Disease (COPD) in the laboratory at Glenfield Hospital to see how energy is delivered to the leg muscles during exercise.

18 Nov 2009

Drug market for acute ischemic stroke to reach $450M in 2018

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that sales of agents to treat acute ischemic stroke will remain relatively flat over the next decade, increasing from $360 million in 2008 to $450 million in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

18 Nov 2009

New neuroimaging techniques yield new insights on Alzheimer's disease

Brain imaging can offer a window into risk for diseases such as Alzheimer's disease (AD). A study conducted at the University of Kansas School of Medicine demonstrated that genetic risk is expressed in the brains of even those who are healthy, but carry some risk for AD. The results of this study are published in the November 2009 issue of the Journal of Alzheimer's Disease.

18 Nov 2009

Albireo completes A3309 phase 1b study in patients with chronic idiopathic constipation

Albireo today announced the completion of a phase 1b study showing a favorable tolerability and safety profile of A3309 in patients with chronic idiopathic constipation. In addition, the data revealed appropriate efficacy signals in this patient population. A3309 is a first in class compound developed for the treatment of chronic idiopathic constipation and constipation-predominant Irritable Bowel Syndrome (IBS-C).

18 Nov 2009

Medical Condition News

Study: Larger dose of ARBs is more effective in heart failure patients

Gene that tells embryonic stem cells when to stop producing neurons identified

A fact-based media briefing on bipolar disorder in Nova Scotia

Pluristem’s PLX-PAD holds promise for critical limb ischemia

The Center for Modeling Optimal Outcomes discovers causal path of autism

Cancer-fighting protein successfully placed directly into solid tumors and turned on

Findings of Merck's anacetrapib phase IIb study presented at the AHA sessions

Cardiologists detect atherosclerosis in ancient Egyptian mummies

Ambrisentan improves health and exercise capacity of PAH patients, find researchers

CRESTOR reduces major cardiovascular events in women by 46%

Developmental biologists to participate in $100 million federal 'Bench to Bassinet' network

Data demonstrate that danger of low levels of HDL is not reduced by statin treatment

World's first intra-arterial cerebral infusion of Avastin directly into a patient's malignant brain tumor

Updated clinical data from Poniard Pharmaceuticals' picoplatin Phase 2 trial announced

NeoPharm presents LE-DT Phase I data at the AACR conference

Transcendental Meditation may be effective in reducing BP and psychological distress

New research may play a vital role in assisting patients with chronic lung disease

Drug market for acute ischemic stroke to reach $450M in 2018

New neuroimaging techniques yield new insights on Alzheimer's disease

Albireo completes A3309 phase 1b study in patients with chronic idiopathic constipation

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News